Immunotherapy in Hepatocellular Carcinoma: Is There a Light at the End of the Tunnel?

Cancers (Basel) · 2019 · PMC6721326 · PMID 31366113

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

However, the results showed a trend favoring pembrolizumab with longer median OS (HR = 0.78; CI: 0.61–0.99) and PFS (HR = 0.78; CI: 0.61–0.99).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.